Stock Price Quote

WOCKHARDT LTD.

NSE : WOCKPHARMABSE : 532300ISIN CODE : INE049B01025Industry : Pharmaceuticals & DrugsHouse : Wockhardt
BSE1730.6543.45 (+2.58 %)
PREV CLOSE ( ) 1687.20
OPEN PRICE ( ) 1698.35
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 44794
TODAY'S LOW / HIGH ( )1670.65 1739.00
52 WK LOW / HIGH ( )560.25 1870
NSE1730.8043.5 (+2.58 %)
PREV CLOSE( ) 1687.30
OPEN PRICE ( ) 1689.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1730.80 (378)
VOLUME 882489
TODAY'S LOW / HIGH( ) 1670.50 1739.90
52 WK LOW / HIGH ( )560.2 1868.8
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 08-07 1999
Management Info
Habil Khorakiwala - Chairman Murtaza Khorakiwala - Managing Director
Registered Office

Address D-4, M. I. D. C,Chikalthana, ,
Chhatrapati Sambhajinagar - (Aurangabad),
Maharashtra-431006

Phone 0240-6632222 / 6694444

Email investorrelations@wockhardt.com

Website www.wockhardt.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

06Jun Wockhardt eyeing to launch new antibio
Wockhardt is eyeing to launch its new antibiotic -- ZAYNICH in second ha..
05Jun Wockhardt informs about investor prese
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
22May Wockhardt informs about annual secret
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure R..
09Apr Wockhardt’s arm incorporates Wholly Ow
Wockhardt’s subsidiary -- Wockhardt Bio AG has incorporated a new Wholly..
01Apr Wockhardt informs about press release
Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit400-120
Gross Profit 400 -120
Operating Profit 12003550
Net Sales 355014020

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  31529.10 (1.67%)
M.Cap ( in Cr)66997.14
Sanofi Cons. Health (BSE)
peergroup  5075.20 (2.17%)
M.Cap ( in Cr)11688.50
JB Chem & Pharma (BSE)
peergroup  1771.25 (5.98%)
M.Cap ( in Cr)27657.06
Divi's Lab (BSE)
peergroup  6589.85 (1.49%)
M.Cap ( in Cr)174939.81
Ajanta Pharma (BSE)
peergroup  2585.30 (1.62%)
M.Cap ( in Cr)32293.52

Shareholding Pattern

MUTUAL FUNDS/UTI 7.56%
PROMOTERS 49.09%
NON-INSTITUTION 33.49%
FI/BANKS/INSURANCE 0.51%
GOVERNMENT 0.02%
FII 0%

About Wockhardt Ltd.

Wockhardt Ltd. was incorporated in the year 1999. Its today's share price is 1730.65. Its current market capitalisation stands at Rs 28120.56 Cr. In the latest quarter, company has reported Gross Sales of Rs. 11560 Cr and Total Income of Rs.11950 Cr. The company's management includes Rashmi Mamtura, Zahabiya Khorakiwala, Murtaza Khorakiwala, Huzaifa Khorakiwala, Ahmad Javed, Amelia Fernandes, Akhilesh Gupta, Vinesh Kumar Jairath, Habil Khorakiwala.

It is listed on the BSE with a BSE Code of 532300 , NSE with an NSE Symbol of WOCKPHARMA and ISIN of INE049B01025. It's Registered office is at D-4, M. I. D. C,Chikalthana, Chhatrapati Sambhajinagar - (Aurangabad)-431006, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Arthur Andersen & Associates, BSR & Co LLP, Haribhakti & Co, Haribhakti & Co LLP, SR Batliboi & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.